Breaking Finance News

JPMorgan downgraded Patheon N.V. (NYSE:PTHN) from Overweight to Neutral in a report released today.

JPMorgan has downgraded Patheon N.V. (NYSE:PTHN) from Overweight to Neutral in a report released on 6/8/2017.

Yesterday Patheon N.V. (NYSE:PTHN) traded 0.00% even at $34.81. The company’s 50-day moving average is $34.98 and its 200-day moving average is $34.98. The last stock close price is down 0.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 229,751 shares of the stock were exchanged, up from an average trading volume of 0

See Chart Below

Patheon N.V. (NYSE:PTHN)

Patheon N.V. has a 52 week low of $24.45 and a 52 week high of $35.02 with a P/E ratio of 44.85 The company’s market cap is currently $0.

About Patheon N.V. (NYSE:PTHN)

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.